Valosin-containing protein Asp395Gly mutation in a patient with frontotemporal dementia: a case report

Ryota Kobayashi1, Hiroya Naruse2, Shinobu Kawakatsu3

  • 1Department of Psychiatry, Yamagata University School of Medicine, 2-2-2 Iidanishi, Yamagata, 990-9585, Japan. ryo.kobayashi@med.id.yamagata-u.ac.jp.

BMC Neurology
|November 4, 2022
PubMed
Abstract

Insights

Valosin-containing protein (VCP) gene variants can cause frontotemporal dementia (FTD). A patient with sporadic FTD and a VCP p.Asp395Gly variant, without muscle or bone issues, was identified, suggesting tauopathy.

Area of Science:

  • Neuroscience
  • Genetics
  • Neuropathology

Background:

  • Valosin-containing protein (VCP) gene variants are linked to frontotemporal dementia (FTD), Paget's disease, and inclusion body myopathy.
  • Previously identified VCP variants cause frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP).
  • A recent report linked VCP p.Asp395Gly to familial FTD with tauopathy (neurofibrillary tau tangles, NFT), not FTLD-TDP.

Observation:

  • A 62-year-old man presented with behavioral changes and executive dysfunction, diagnosed with behavioral variant FTD.
  • Brain imaging showed frontal lobe atrophy and hypoperfusion.
  • Extensive testing revealed no muscle or bone disease, and cerebrospinal fluid (CSF) analysis suggested NFT accumulation.

Findings:

  • Genetic analysis identified the VCP p.Asp395Gly variant in the patient with sporadic FTD.
  • This case represents a likely sporadic FTD presentation without the typical muscle or bone comorbidities associated with other VCP variants.
  • Cerebrospinal fluid tau levels indicated a potential tauopathy, aligning with recent findings for this specific VCP variant.

Implications:

  • The VCP p.Asp395Gly variant can cause sporadic FTD, even without muscle or bone disease.
  • Genetic screening for VCP variants should be considered in both familial and sporadic FTD cases.
  • This finding expands the phenotypic spectrum of VCP-related disorders and highlights the importance of genetic testing in atypical FTD presentations.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
626
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.7K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
246
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.8K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
Point and Frameshift Mutations01:30

Point and Frameshift Mutations

Point mutations are genetic alterations involving the change of a single nucleotide base pair in DNA. Depending on how the alteration affects protein synthesis, they can lead to various consequences.Point mutations fall into the following types:Silent mutations occur when a nucleotide change does not alter the amino acid sequence due to the redundancy of the genetic code. For instance, changing ACC to ACA still encodes threonine, leaving the protein function unaffected. This occurs because...
58